Optimizing Site Feasibility in Clinical Trials for Ultra-Rare Diseases

Why Site Feasibility is Especially Crucial for Ultra-Rare Trials

In ultra-rare disease clinical trials, where eligible patient populations may be limited to only a few individuals per country—or even globally—site feasibility takes on an elevated level of importance. A misstep in site selection can lead to zero enrollment, delays, protocol amendments, or even trial failure. Sponsors cannot afford traditional high-volume approaches or selection based on historical metrics alone.

Feasibility assessments in these studies must focus on disease-specific patient availability, diagnostic capacity, investigator expertise in rare pathologies, and local regulatory familiarity with orphan drug protocols. Effective feasibility processes enable targeted recruitment, reduced site burden, and streamlined regulatory navigation. Agencies like the EMA and FDA expect robust documentation showing rationale behind site selection for such sensitive research populations.

Challenges in Identifying Feasible Sites for Ultra-Rare Conditions

Key challenges in site feasibility include:

• Scattered patient populations: Patients may be spread across countries or continents
• Limited diagnostic infrastructure: Especially for genotypically defined subgroups
• Low investigator experience: Physicians may have managed only 1–2 cases ever
• Ethical and regulatory complexity: Local authorities may lack rare disease trial precedents

For example, in a lysosomal storage disorder trial targeting 12 global patients, one high-profile academic site failed to enroll due to lack of genetic testing facilities, despite clinical interest. Early feasibility vetting could have flagged this mismatch.

Steps in Conducting Rare Disease Feasibility Assessments

A structured feasibility process for ultra-rare studies involves:

1. Feasibility Questionnaire: Tailored to assess site’s access to target population, diagnostic tools, and previous rare disease experience
2. Patient Funnel Analysis: Estimating the number of patients diagnosable, consentable, and willing to participate within study timelines
3. Protocol Complexity Assessment: Determining alignment between study demands and site capabilities (e.g., need for sedation MRI, long-term follow-up)
4. Regulatory Landscape Review: Understanding IRB timelines, import/export rules, and pediatric approval pathways
5. Site Qualification Visits (SQVs): Virtual or on-site walkthroughs for infrastructure and PI engagement evaluation

These steps, executed sequentially, provide a risk-profiled site readiness score and inform go/no-go decisions with clarity.

Patient Mapping and Registry Utilization

Feasibility should include proactive engagement with national rare disease registries, patient advocacy groups, and reference centers. Mapping where patients are diagnosed, managed, and treated—not just where hospitals exist—is critical.

For instance, India’s Clinical Trial Registry and national disease registries can help sponsors assess where most of the genetically confirmed cases are clustered. Such data may suggest partnerships with local genetic labs or patient support NGOs to ensure effective outreach during recruitment.

Case Study: Multi-National Feasibility for a Pediatric Enzyme Replacement Trial

A sponsor planning a global trial for a pediatric metabolic disorder with 18 patients worldwide began by distributing a standard feasibility questionnaire. Despite 30 responses, only 8 sites could confirm access to more than 1 patient, and only 4 had proven ERT experience. Post-screening, 5 were qualified through remote SQVs. This focused approach led to 95% of planned enrollment in under 8 months.

Such precision feasibility ensured optimal site-to-patient ratio, regulatory readiness, and engagement from experienced clinicians—drastically reducing trial risk.

Feasibility in Decentralized or Hybrid Trial Models

Decentralized trial (DCT) elements are gaining traction in rare disease research. Feasibility must now include assessment of:

• Telemedicine infrastructure for follow-ups
• Home health visit availability for sample collection or infusions
• Local lab capabilities for urgent assessments
• eConsent and remote monitoring readiness

Ultra-rare disease trials may enroll just one or two patients per site—making hybrid or DCT components not just helpful but essential for trial execution.

Regulatory Expectations and Documentation

Agencies such as EMA, FDA, and PMDA expect site selection to be justified in the Clinical Trial Application (CTA) dossier. Key documents include:

• Site feasibility reports and questionnaires
• Rationale for geographic distribution of sites
• Documentation of site capabilities for protocol-specific procedures
• Backup site lists and criteria for substitution

During GCP inspections, regulators may question why non-performing sites were selected or why local approvals were delayed. A clear feasibility traceability matrix helps defend site selection rationale.

Conclusion: Precision Feasibility is a Cornerstone of Rare Disease Trial Success

In ultra-rare clinical trials, each patient is precious—and each site is strategic. A well-executed feasibility process minimizes trial risk, optimizes resource use, and accelerates timelines. Sponsors should invest in tailored feasibility assessments that go beyond numbers and focus on true site readiness for complex, high-stakes research.

From infrastructure and personnel to patient access and regulatory history, every data point matters. Precision in feasibility leads to precision in outcomes—both scientific and operational.

Integrating Patient Voices Through Advisory Boards in Rare Disease Trials

The Importance of Patient Engagement in Trial Design

In rare disease clinical trials, involving patients early in the design process is no longer optional—it’s essential. Given the complex, lifelong impact of many rare diseases, patients and caregivers offer unique insights into daily challenges, treatment burdens, and outcome expectations that may not be captured by sponsors or investigators alone.

Patient Advisory Boards (PABs) act as formal structures to incorporate these voices into trial planning, ensuring protocols are relevant, ethical, and feasible. Their input enhances recruitment, retention, data quality, and regulatory acceptance.

Regulatory bodies such as the FDA and EMA increasingly recognize the role of patient-focused drug development. In fact, the FDA’s Patient-Focused Drug Development (PFDD) initiative encourages direct patient involvement in trial design and labeling decisions.

What Is a Patient Advisory Board?

A Patient Advisory Board is a group of patients, caregivers, advocates, and sometimes clinicians who provide structured feedback on clinical trial protocols, endpoints, consent forms, and participant communication. These boards typically meet before and during study execution and are often consulted in long-term follow-up phases as well.

For rare disease studies, these boards often include:

• Patients or caregivers with lived experience of the condition
• Representatives from national or global rare disease advocacy organizations
• Independent patient engagement consultants
• Clinical trial design experts (sometimes as observers)

The composition ensures diverse viewpoints and balances scientific rigor with real-world feasibility.

Benefits of Patient Advisory Boards in Rare Disease Research

Integrating a PAB into trial planning brings multiple advantages:

• Protocol feasibility: Assess whether proposed procedures, visit schedules, or interventions are practical and tolerable
• Outcome relevance: Validate that endpoints reflect what matters to patients (e.g., mobility, pain, independence)
• Informed consent quality: Help design clear, compassionate, and culturally appropriate consent materials
• Recruitment strategies: Improve messaging, outreach, and trust-building with patient communities
• Retention support: Identify potential trial burdens that could increase drop-out rates and recommend mitigation

In one example, a rare metabolic disorder trial saw a 35% improvement in enrollment after revising patient materials based on PAB recommendations.

Steps to Establish a Patient Advisory Board

Establishing a robust, credible PAB involves several key steps:

1. Define objectives: Determine the board’s role (e.g., protocol review, communication review, ongoing feedback)
2. Engage stakeholders: Partner with advocacy groups and clinician networks to identify suitable members
3. Formalize structure: Draft a governance charter, confidentiality agreements, and compensation policies
4. Facilitate collaboration: Use neutral facilitators or CROs to moderate meetings and ensure all voices are heard
5. Document impact: Keep records of PAB recommendations and how they were addressed (critical for regulatory submissions)

Advisory boards can be ad hoc (project-based) or standing (ongoing for a sponsor’s rare disease pipeline), depending on trial timelines and organizational strategy.

Timing and Frequency of Engagement

To maximize value, PABs should be involved early—ideally during the feasibility or protocol concept phase. This timing allows their feedback to influence trial design before IRB/EC submissions or budget finalizations. Common engagement points include:

• Feasibility assessments and site selection
• Protocol finalization and consent form drafting
• Trial initiation and recruitment campaigns
• Mid-study adjustments or retention challenges
• Post-trial follow-up planning and results communication

Advisory boards typically meet 2–4 times per year, depending on the trial phase and complexity.

Regulatory and Ethical Considerations

While advisory boards are not formal regulatory bodies, their contributions must align with Good Clinical Practice (GCP) and ethical research standards. Key considerations include:

• Informed involvement: Members must understand the scope, limits, and confidentiality of their role
• Transparency: Disclose any compensation or conflicts of interest
• Respect for diversity: Include voices across age, gender, socioeconomic background, and cultural identity
• Data privacy: Avoid sharing patient-level data unless necessary and with consent

Some trial sponsors include PAB summaries in their clinical trial applications or regulatory briefing documents to demonstrate commitment to patient-centric design.

Real-World Case Study: Duchenne Muscular Dystrophy Trial

In a global phase III trial for Duchenne Muscular Dystrophy (DMD), the sponsor formed a 12-member advisory board consisting of adolescent patients, caregivers, and representatives from three advocacy groups. The board reviewed protocol drafts, site burden estimates, and eDiary formats.

Recommendations included reducing redundant assessments, increasing flexibility in visit windows, and revising inclusion criteria to prevent unnecessary exclusions. After implementing these changes, trial enrollment accelerated by 40% and retention reached 94% at the 12-month mark.

Tools and Platforms for Effective Engagement

Several tools can streamline PAB operations:

• Virtual collaboration tools: Zoom, Teams, and collaborative document platforms allow for global participation
• Asynchronous feedback platforms: Tools like TrialAssure or PatientsLikeMe support surveys and online discussion threads
• Translation services: For multinational boards, language access is critical for inclusive dialogue
• Engagement dashboards: Track impact metrics, feedback themes, and implementation progress

Use of these platforms not only improves board operations but also reduces operational cost, particularly for rare disease trials spanning multiple countries and time zones.

Conclusion: Centering Patients for Ethical and Effective Trial Design

Patient Advisory Boards are powerful instruments for embedding patient needs and realities into rare disease clinical trials. They bridge the gap between protocol design and lived experience, promoting both ethical integrity and operational success.

By forming and empowering advisory boards, sponsors and CROs demonstrate a long-term commitment to patient-centered research. In doing so, they not only enhance trial performance but also build lasting trust with the rare disease communities they aim to serve.

Integrating the Patient Voice into Rare Disease Trial Design

Why Patient Feedback is Critical in Rare Disease Protocol Development

Rare disease clinical trials often face unique challenges: small patient populations, variable disease progression, and high clinical heterogeneity. In this context, designing effective and feasible protocols requires not just scientific expertise, but also meaningful input from the very individuals who will participate in the trial—patients and caregivers.

Incorporating patient feedback helps identify protocol features that may be burdensome, irrelevant, or misaligned with real-world needs. It enhances enrollment, reduces dropouts, and improves the overall quality of the study. Regulatory agencies such as the FDA and EMA increasingly support patient-centered development models, encouraging early and ongoing engagement with the patient community.

Methods of Collecting Patient Feedback During Protocol Development

There are multiple ways sponsors and researchers can collect structured, actionable input from rare disease patients, including:

• Patient Advisory Boards (PABs): Groups of patients or caregivers who review trial plans and provide structured feedback
• Focus groups: Facilitated sessions that explore patient perspectives on burdens, procedures, and expectations
• Surveys: Targeted questionnaires to assess trial acceptability, visit frequency, travel demands, and perceived risks
• Community consultations: Meetings with advocacy groups or rare disease networks

For example, a sponsor planning a Phase II trial for a rare neuromuscular disorder conducted a digital focus group that revealed patients considered bi-weekly travel to a site unsustainable. As a result, the protocol was amended to include local infusion options.

Impact of Patient Feedback on Protocol Feasibility and Enrollment

When patients are engaged early, they often identify protocol elements that would otherwise impair participation. Common adjustments include:

• Reducing frequency of invasive procedures
• Allowing telemedicine or remote data collection
• Shortening clinic visit duration
• Eliminating redundant assessments
• Clarifying endpoint relevance to daily functioning

These changes not only make the study more tolerable but also directly improve recruitment and retention. In rare disease trials, where every participant counts, even small enhancements in design can significantly impact trial success.

Examples of Patient-Centric Trial Adjustments

Several high-profile rare disease trials have implemented protocol changes based on patient input. Here are a few illustrative cases:

Regulatory Encouragement for Patient Engagement

Global regulatory authorities have taken active steps to endorse patient-focused protocol design:

• FDA’s PFDD Framework: Encourages sponsors to include patient experience data in NDAs and BLAs
• EMA’s Patient Input Guidance: Advises sponsors to engage patient groups during protocol development
• ICH E8(R1): Revised to incorporate “fit-for-purpose” design based on patient needs

Clinical trial protocols that demonstrate genuine integration of patient voice are viewed more favorably during regulatory review, especially when they improve relevance and reduce trial burden.

Implementing Feedback While Maintaining Scientific Integrity

One concern raised by sponsors is whether patient-informed changes could compromise scientific rigor. However, the two are not mutually exclusive. In fact, patient-centric protocols are often more robust because they consider real-world implementation challenges.

Strategies to maintain rigor include:

• Pre-specifying criteria for feedback inclusion (e.g., ≥50% of patients cite same issue)
• Modeling statistical impact of design changes
• Using adaptive trial features to test multiple protocol scenarios

In one instance, a rare metabolic disorder trial reduced the number of lumbar punctures from five to three after patients cited intense anxiety. The endpoint quality was maintained by using more frequent blood-based biomarkers.

Embedding Feedback Loops in Protocol Lifecycles

Engagement should not end at trial start. Building feedback mechanisms throughout the study allows mid-course corrections and improved patient satisfaction. Recommended approaches include:

• Patient-reported outcome (PRO) collection on trial experience
• Quarterly advisory board check-ins
• Anonymous feedback forms post-visit
• Protocol amendment consultations for major changes

Such continuous improvement loops can help address emerging patient concerns, especially in long-term or open-label extension studies.

Conclusion: Elevating the Role of Rare Disease Patients in Research

Patients living with rare diseases bring unique insights into their conditions, treatments, and lived realities. Leveraging this expertise in protocol design ensures that clinical trials are not only scientifically valid but also ethically and practically grounded. Incorporating patient feedback enhances recruitment, adherence, and real-world relevance—key factors for success in rare disease development.

By embedding participatory design into the DNA of clinical research, sponsors, investigators, and regulators can collectively move toward a more inclusive, responsive, and impactful model of rare disease innovation.

Integrating Natural History Data into Interventional Study Design for Rare Diseases

Introduction: Why Bridging Natural History and Interventional Studies Matters

Natural history studies provide critical insight into disease progression, phenotypic variability, and baseline clinical trajectories. In rare disease research, where randomized controlled trials (RCTs) may not always be feasible, these observational datasets serve as a foundation for designing interventional studies. Bridging the two paradigms—non-interventional and interventional—is essential for efficient, ethically sound, and scientifically robust clinical development.

This bridge enables better-informed eligibility criteria, improved endpoint selection, faster trial startup, and enhanced regulatory engagement. Moreover, regulators such as the FDA and EMA increasingly accept natural history data to justify single-arm trials, external control arms, and surrogate endpoints in rare disease trials. However, the transition from registry to trial requires careful planning, harmonized data structures, and ethical re-engagement with participants.

Assessing the Utility of Natural History Data in Trial Design

To determine whether natural history data can effectively support an interventional study, sponsors must evaluate:

• Data Completeness: Sufficient longitudinal coverage for baseline and disease progression analysis
• Variable Consistency: Alignment of measured outcomes with proposed trial endpoints
• Population Representativeness: Whether registry participants reflect the trial’s target population
• Regulatory Acceptability: Quality and traceability of the dataset per GCP and data standards (e.g., CDISC)

A rare neurodegenerative disorder registry that captured motor milestones and biomarker levels over five years was successfully used to inform a Phase II/III trial in the same population, bypassing the need for a traditional control arm.

Designing Eligibility Criteria Based on Registry Insights

One major advantage of bridging is the ability to define trial inclusion/exclusion criteria based on real-world patient distributions. Natural history data can identify:

• Common phenotypes and disease subtypes
• Age ranges where progression is most predictable
• Baseline characteristics (e.g., enzyme levels, mobility scores) linked to faster or slower progression

For example, a registry on pediatric leukodystrophies showed that children aged 2–6 had the most consistent decline in neurological scores, which helped narrow eligibility in a subsequent trial to this age group, thereby reducing heterogeneity and improving statistical power.

Endpoint Selection Informed by Natural History Trends

One of the most significant contributions of natural history data is in identifying clinically meaningful and measurable endpoints. These may include:

• Time-to-event metrics: Time to loss of ambulation, ventilation, or cognitive decline
• Rate-based endpoints: Annualized decline in a biomarker or functional score
• Milestone-based endpoints: Acquisition or loss of developmental milestones

Natural history studies that demonstrate stability in a given endpoint can also justify its use as a surrogate marker in single-arm trials.

Patient Retention and Continuity from Registry to Trial

Participants enrolled in a registry may be pre-positioned for participation in an interventional trial, offering several advantages:

• Reduced recruitment timelines
• Known compliance history and data availability
• Familiarity with site staff and procedures

However, transitioning participants requires fresh informed consent, re-screening, and often ethics re-approval. Maintaining participant trust through transparent communication and optional participation models is critical.

Real-World Example: Transitioning a Dystrophic Epidermolysis Bullosa (DEB) Registry to a Phase III Trial

A multinational DEB registry collected data on wound healing rates and quality of life over four years. Based on this data, the sponsor identified the most appropriate primary endpoint for a gene therapy trial. Over 60% of the registry patients were successfully re-enrolled into the Phase III trial, minimizing startup time and maximizing data continuity.

“`html

Protocol Development Based on Observational Insights

Natural history studies provide more than just endpoints—they also inform:

• Visit schedules: Based on rate of change observed in the registry
• Safety monitoring: Identification of high-risk subgroups
• Dose timing: Aligned with disease progression patterns

This results in protocols that are more feasible, reduce participant burden, and anticipate common deviations. For example, a study on a mitochondrial disorder used registry insights to schedule visits every 3 months instead of monthly, based on stability in metabolic markers.

Site Readiness and Training for Transition

Sites participating in both observational and interventional phases benefit from continuity, but they also need to undergo formal transition protocols:

• GCP training refreshers and protocol-specific training
• System validation for EDC platforms
• Logistics for IP handling, blinding, and safety reporting

Documentation of this transition must be clear for regulatory audit purposes. Some sponsors create a Site Transition Toolkit with SOPs, checklists, and templates for seamless onboarding.

Regulatory Expectations and Acceptability

Bridging observational data into trial protocols is subject to regulatory scrutiny. Agencies like the FDA and EMA provide the following guidance:

• FDA: Accepts external controls or single-arm trials supported by natural history data under the Accelerated Approval pathway
• EMA: Recognizes use of natural history registries in orphan designation and scientific advice procedures
• Japan PMDA: Encourages early engagement for rare diseases leveraging existing datasets

Early engagement with agencies via Type B or Scientific Advice meetings can validate your bridging strategy.

Data Harmonization and Structural Mapping

To merge natural history data into a regulatory-grade trial database, structural compatibility is crucial. Sponsors should align observational and interventional data using:

• CDISC CDASH/SDTM standards
• Common Data Elements (CDEs) from NIH, NORD, or global consortia
• Standard coding systems (e.g., MedDRA, WHO-DD)

Metadata mapping and documentation of variable transformations are essential to maintain data traceability and integrity for submission.

Ethical and Legal Considerations in Registry-to-Trial Conversion

Converting a registry cohort into a clinical trial population involves re-consenting participants. Ethical considerations include:

• Transparency about the interventional nature of the new study
• Provision for opt-out without penalty or loss of care
• IRB/EC review of any new risks or burdens

In some jurisdictions, such as the EU, General Data Protection Regulation (GDPR) mandates new informed consent when the purpose of data use changes significantly.

Conclusion: A Strategic Pathway for Rare Disease Innovation

Bridging natural history and interventional studies offers a streamlined, patient-centric, and scientifically grounded approach to rare disease drug development. By leveraging observational data for endpoint definition, eligibility refinement, and patient recruitment, sponsors can reduce development timelines, ethical burdens, and regulatory risk.

As real-world evidence becomes a more accepted part of clinical development, mastering the transition from observational to interventional paradigms will be essential for bringing innovative treatments to patients with rare diseases faster and more efficiently.

How to Effectively Manage Complex Protocols in Ultra-Rare Disease Clinical Trials

Why Protocol Complexity is Unavoidable in Ultra-Rare Disease Trials

Ultra-rare diseases—those affecting fewer than 1 in 50,000 individuals—pose immense challenges for clinical development. Due to limited scientific knowledge, lack of standardized endpoints, and heterogeneous patient presentations, protocols for such trials are inherently complex. However, this complexity, if not managed carefully, can lead to delays, high protocol deviation rates, and poor data quality.

Trials for conditions like Niemann-Pick Type C, Batten Disease, or ultra-rare mitochondrial disorders often require customized diagnostic tools, novel biomarkers, long-term follow-up, and multidisciplinary endpoints. These studies must also operate under intense regulatory scrutiny and tight timelines, especially when accelerated pathways (e.g., Breakthrough Therapy or PRIME) are involved.

Key Drivers of Protocol Complexity in Ultra-Rare Studies

Several unique factors drive complexity in these studies:

• Broad eligibility criteria: To compensate for low patient availability, protocols include diverse phenotypes, complicating data interpretation.
• Novel endpoints: Many trials rely on surrogate, composite, or biomarker endpoints not yet validated by regulators.
• Multiple procedures: Including genetic testing, specialty labs, imaging (e.g., brain MRI), and functional assessments.
• Long duration: Follow-up often extends 12–36 months post-treatment to assess disease progression or stabilization.
• Cross-disciplinary teams: Trials involve neurologists, metabolic specialists, geneticists, and even behavioral scientists.

Protocol complexity is sometimes necessary—but must be counterbalanced with operational feasibility and patient burden considerations.

Strategies for Simplifying Protocol Design Without Compromising Science

To manage complexity, trial designers must start with a rigorous protocol optimization process:

• Protocol mapping: Visually map each procedure and visit to identify redundancies or non-critical assessments.
• Stakeholder input: Include investigators, caregivers, and patient advocacy groups during protocol development to flag burden-heavy elements.
• Data prioritization: Rank each data point as essential, supportive, or exploratory to reduce unnecessary collections.
• Regulatory alignment: Pre-IND and Scientific Advice meetings can guide endpoint selection and reduce post-submission rework.

Case example: A sponsor removed three non-essential exploratory labs after consulting EMA, reducing patient visit times by 25%.

Using Adaptive Designs to Manage Complexity

Adaptive designs allow pre-specified protocol modifications based on interim data. In ultra-rare trials, this approach can:

• Optimize sample size dynamically
• Stop early for futility or efficacy
• Adjust dosing arms or stratification variables

However, these designs require detailed statistical modeling and transparent dialogue with regulatory agencies to ensure acceptability. Sponsors must also train sites and data monitoring committees to understand adaptation rules and triggers.

Decentralized Elements to Reduce Patient and Site Burden

Because patients may travel hundreds of kilometers to participate, integrating decentralized clinical trial (DCT) components can dramatically improve participation and retention:

• Home health visits: For vitals, lab draws, and questionnaire administration
• Remote assessments: ePROs, telehealth visits, and wearable devices
• Local labs or imaging: Reduce travel by partnering with regional facilities

One ultra-rare epilepsy trial in Latin America implemented 60% of its assessments via remote platforms, achieving 90% visit compliance and zero missed doses.

Training and Support for Investigators and Site Staff

Complex protocols require a higher level of engagement and support from trial teams. Sponsors must:

• Conduct disease-specific and protocol-specific training for investigators and sub-investigators
• Offer 24/7 medical monitor access to resolve eligibility or safety queries
• Use protocol pocket guides or mobile apps for quick reference

Additionally, real-time query resolution via centralized monitoring can preempt protocol deviations and enhance data consistency.

Regulatory Examples of Complex Protocol Acceptance

Health authorities are aware of the unique challenges in ultra-rare diseases and often show flexibility. For example:

• The FDA accepted a single-arm trial with natural history comparator for Duchenne Muscular Dystrophy under the Accelerated Approval pathway.
• The EMA endorsed a hybrid endpoint combining biomarkers and caregiver-reported outcomes for a Batten disease study.

These examples underscore the importance of early and transparent engagement with agencies to manage complexity proactively.

Managing Protocol Amendments and Mid-Trial Adjustments

Even with rigorous planning, ultra-rare studies often require amendments due to recruitment challenges, new biomarker data, or safety findings. To mitigate amendment burden:

• Use modular protocol templates for easier edits
• Plan amendment impact assessments (logistics, data, training)
• Inform IRBs and sites early, and provide clear summary of changes

Maintain a version control tracker and train all site staff on updates before implementing changes.

Conclusion: Operationalizing Complex Protocols Requires Strategic Planning

Ultra-rare disease trials will always involve some level of complexity. However, through adaptive designs, stakeholder engagement, decentralized elements, and rigorous training, sponsors can execute these protocols without overwhelming patients or sites. The key lies in striking a balance—between scientific robustness and operational pragmatism.

As more sponsors enter the ultra-rare space, those who excel at protocol simplification, training, and site support will see faster enrollment, better retention, and more credible data—paving the way for successful approvals in this high-need therapeutic area.